AU2001282551A1 - Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases - Google Patents

Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Info

Publication number
AU2001282551A1
AU2001282551A1 AU2001282551A AU8255101A AU2001282551A1 AU 2001282551 A1 AU2001282551 A1 AU 2001282551A1 AU 2001282551 A AU2001282551 A AU 2001282551A AU 8255101 A AU8255101 A AU 8255101A AU 2001282551 A1 AU2001282551 A1 AU 2001282551A1
Authority
AU
Australia
Prior art keywords
heart
preventives
remedies
cell apoptosis
apoptosis inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282551A
Inventor
Tatsuhiko Kaneko
Haruhide Kimura
Seiichi Tanida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001282551A1 publication Critical patent/AU2001282551A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
AU2001282551A 2000-08-31 2001-08-30 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases Abandoned AU2001282551A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000262757 2000-08-31
JP2000-262757 2000-08-31
PCT/JP2001/007468 WO2002018356A1 (en) 2000-08-31 2001-08-30 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Publications (1)

Publication Number Publication Date
AU2001282551A1 true AU2001282551A1 (en) 2002-03-13

Family

ID=18750391

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282551A Abandoned AU2001282551A1 (en) 2000-08-31 2001-08-30 Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases

Country Status (5)

Country Link
US (1) US6794383B2 (en)
EP (1) EP1325918A4 (en)
AU (1) AU2001282551A1 (en)
CA (1) CA2419838A1 (en)
WO (1) WO2002018356A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020719A1 (en) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and use thereof
AU2003235122A1 (en) 2002-04-26 2003-11-10 Takeda Chemical Industries, Ltd. Cell death inhibitor
WO2004060881A1 (en) * 2002-12-05 2004-07-22 Takeda Pharmaceutical Company Limited 1,3-benzothiazinone derivatives, process for producing the same and use thereof
WO2006132438A1 (en) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 1,3-benzothiazinone derivative and use thereof
WO2008035823A1 (en) 2006-09-22 2008-03-27 Takeda Pharmaceutical Company Limited Cell death inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470168A (en) * 1967-03-31 1969-09-30 American Home Prod 2-substituted-4h-1,3-benzothiazin-4-one derivatives
IT1254884B (en) * 1992-04-16 1995-10-11 Italfarmaco Spa BENZOSSAZINONI AND BENZOTIAZINONI WITH CARDIOVASCULAR ACTIVITY
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors

Also Published As

Publication number Publication date
EP1325918A1 (en) 2003-07-09
US6794383B2 (en) 2004-09-21
WO2002018356A1 (en) 2002-03-07
US20030186971A1 (en) 2003-10-02
CA2419838A1 (en) 2003-02-18
EP1325918A4 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2001289120A1 (en) Implantable heart assist devices and methods
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2002241520A1 (en) Blood assessment of injury
AU2003256253A1 (en) Aerosol for medical treatment and methods
AUPQ893200A0 (en) Medical residue treatment
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001265264A1 (en) Devices and methods for assisting natural heart function
AU2003289330A1 (en) Preventives and/or remedies for central diseases
AU2003221173A1 (en) Placenta-origin mesenchymal cells and medicinal use thereof
AU8026200A (en) Treatment of heart disease with cox-2 inhibitors
AUPQ877300A0 (en) Topical treatment of skin
AU2001233208A1 (en) Human sulfatases
AUPR074500A0 (en) Treatment of t cell disorders
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU3896900A (en) Treatment of pain
AU2001282551A1 (en) Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases
AU3978700A (en) Medical use
AU7106300A (en) Treatment of skin disorders
HK1045260A1 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use.
AU2001286341A1 (en) Therapeutic bio-energy unit
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
AU2001280133A1 (en) Preventives and remedies for central nervous system diseases